

The C₂ cytosolic loop of adenylyl cyclase interacts with the activated form of G α s

Marcela Torrejón^a, Anne-Marie Genevière^b, Valentina Echeverría^a, Leonardo Guzmán^a,
María Victoria Hinrichs^a, Juan Olate^{b,*}

^aLaboratorio de Genética Molecular, Departamento de Biología Molecular, Facultad de Ciencias Biológicas, Casilla 160-C, Universidad de Concepción, Concepción, Chile

^bObservatoire Océanologique de Banyuls, Laboratoire Arago, Université Pierre et Marie Curie (Paris VI), Institut National des Sciences de L'Univers, Banyuls-Sur-Mer Cedex, France

Received 13 November 1998

Abstract Using the yeast two-hybrid system, we studied the physical interaction between the complete C₁ and C₂ cytosolic domains of *Xenopus laevis* type 9 (x19C₁, x19C₂) and the C₂ domain of rat type 6 (r6C₂) adenylyl cyclase (AC). Heterodimerization between x19C₁ and x19C₂ and homodimerization between C₂ (but not C₁) domains was observed. Interaction between C₂ and human G α s (hG α s) was also detected and was dependent on G α s activation. In contrast *X. laevis* G α s (xlG α s), which is 92% identical to hG α s, was unable to interact with any of the three AC cytosolic domains tested, corroborating previous findings that showed no effector activation. Through the construction of chimeras, we demonstrated that the amino-terminal half of xlG α s was responsible for the lack of interaction with AC. Chimeras between mouse G α i2 and G α s (N-mG α i2/C-G α s), that have previously shown to activate AC to a higher extent than wild-type G α s, also interacted with the C₂ cytosolic domain and with a higher affinity. Interestingly, N-mG α i2/C-xlG α s chimera was not only able to interact with C₂ but also with the C₁ cytosolic domain.

© 1998 Federation of European Biochemical Societies.

Key words: Adenylyl cyclase; G protein;
Yeast two-hybrid system

1. Introduction

Adenylyl cyclase (AC) is a widely distributed G protein coupled receptor (GPCR) regulated effector system which catalyzes the synthesis of cAMP, a ubiquitous second messenger that mediates diverse cellular responses by activating cAMP-dependent protein kinases. To date, nine different mammalian isoforms have been cloned and characterized from different sources [1–3]. AC isoenzymes differ in their tissue distribution and regulatory properties. With the exception of AC type 9, all of them are stimulated by the active GTP-bound form of G α s and the diterpene forskolin (Fk) [3–7]. Almost all AC (except type 4) are regulated directly or indirectly by Ca²⁺ [3,8,9]. Types 1, 3 and 8 are activated by Ca²⁺-calmodulin, types 5 and 6 are inhibited by Ca²⁺ levels and types 2 and 5 are activated by protein kinases A and C (PKA, PKC) [10–14]. G $\beta\gamma$ heterodimers also modulate the activity of some AC isoforms, activating AC types 2 and 4 and inhibiting type 1 [15–17].

All known mammalian AC isozymes share a predicted topological structure designated as NM₁C₁M₂C₂, containing

a short amino-terminal region (N), two highly hydrophobic domains (M₁ and M₂) that are postulated to contain six trans-membrane helices, and two cytoplasmic domains (C₁ and C₂). The amino-terminal halves of each cytoplasmic domain (C_{1a} and C_{2a}) share a high homology and are 50–90% similar to the corresponding domains of other AC isoforms and only 20–25% similar to the catalytic domains of guanylyl cyclases [3,18]. Recently, expression of a soluble form of a mammalian AC has been achieved, allowing for important biochemical and structural studies of the enzyme [19,20]. When the C_{1a} domain of AC type 1 and the C₂ domain of AC type 2 isoforms (joined by a small linker) were expressed, a soluble and active enzyme was obtained. This enzyme was activated by GTP-G α s and Fk, and inhibited by P-site inhibitors and G $\beta\gamma$ dimers. Expression of the individual domains (C₁ or C₂) exhibited little or no enzymatic activity [20,21]. Interestingly, coexpression of the two AC cytosolic domains as separate entities showed enzymatic activity and regulatory properties of the native enzyme, indicating that non-covalent interactions between C₁ and C₂ are important for catalytic activity [22,23]. Consistent with this idea, crystallographic studies performed by different groups have shown that fragments of both soluble AC cytosolic domains can interact in the presence of Fk, and that only C₂ can form homodimers and physically interact with G α s [24–27]. By using the two-hybrid system, Scholich et al. [28] have identified a 10-amino acid (aa) region within the C₂ domain in AC type 5 that was able to interact with a 112-aa peptide of C_{1b} and showed that this interaction was modulating the stimulation by G α s.

Recently, we reported the cloning and characterization of a *X. laevis* type 9 AC [29], which is activated by the human G α s, but not by its homologous xlG α s, even though both proteins share 92% of identity [30]. In order to try to understand this difference, we have evaluated the direct intermolecular interaction between the human and *Xenopus* G α s and the AC cytosolic domains C₁ and C₂. Using the yeast two-hybrid system we show that only the activated form of the hG α s, but not the xlG α s, was able to interact with the C₂ domain of the enzyme. This is in agreement with the lack of activation of AC by the *Xenopus* G α s subunit, that we had previously reported [30].

2. Materials and methods

2.1. Plasmids construction for the yeast two-hybrid system

Yeast cloning vectors containing the Gal4 DNA-binding domain (pAS2-1) and the GAL4 activating domain (pACT2) were obtained from Clontech. cDNAs containing the entire coding sequence of xlG α s, xlG α s(Q/L), hG α s, and hG α s(Q/L) were excised from their

*Corresponding author. Fax: (33) (56) 41 239687.
E-mail: jolate@udec.cl

respective recombinant vectors with *NcoI* and *SalI* and inserted in-frame into pAS2-1. Chimera 10 (ch10) was constructed by ligation of a mouse *Gxi2 NcoI-Tth111I* cDNA fragment (aa 1–193) to a human *Gxs Tth111I-SalI* cDNA fragment (aa 201–379) and subcloned into pAS2-1 vector. ch10(Q/L) was obtained the same way as ch10, but using the human *Gxs(Q/L) Tth111I-SalI* cDNA fragment. Chimera 9 (ch9) and ch9(Q/L) were synthesized as ch10 and ch10(QL) by using the *xlGxs Tth111I-SalI* or the *xlGxs(Q/L) Tth111I-SalI* cDNA fragments. Chimera 2 (ch2) was originated by ligation of an *hGxs(Q/L) NcoI-BglII* fragment (aa 1–280) to a *xlGxs BglII-SalI* fragment (aa 281–379) and subcloned into the pAS2-1 vector. Chimera 1 (ch1) was constructed by ligation of an *xlGxs(Q/L) NcoI-BglII* fragment (aa 1–280) to an *hGxs BglII-SalI* fragment (aa 281–379) and subcloned into the pAS2-1 vector. AC C₁ and C₂ domains were amplified by PCR using the *X. laevis* AC type 9 (xlAC9) and rat AC type 6 (rAC6) full-length cDNAs as template. The following oligonucleotides were used for the amplification of the different AC fragments: xlAC9C₁ (aa 346–832), forward primer containing an *NcoI* site 5'-CTTTTCAC-CATGGCTGAGGTCCGA-3' and a reverse primer containing a *BamHI* site 5'-AAGGAGTGGATCCTGCAAGGA-3'; xlAC9C₂ (aa 1037–1355), forward primer containing a *BamHI* site 5'-CTGGTGTGGATCCTGAACCGT-3' and a reverse primer containing an *EcoRI* site 5'-GATCCGAATTCTGCCTCACCG-3'; rAC6C₂ (aa 911–1135), forward primer containing a *BamHI* site 5'-TATCTACG-GATCCAACAGGTG-3' and a reverse primer with an *EcoRI* site 5'-CACTGCTGGAATTCGCTAACTGCT-3'. After digestion with the appropriate restriction enzymes, the PCR fragments were subcloned into the pACT2 vector. The same *NcoI-BamHI* xlAC9C₁ PCR fragment was subcloned into pAS2-1, but PCR fragments xlAC9C₂ and rAC6C₂ were first subcloned into the pCEV-29 vector, then excised with *BamHI* and *SalI*, and finally subcloned into the pAS2-1 vector. All constructs were sequenced to confirm the correct reading frames and fusion protein expression was analyzed by Western blot using specific antibodies against GAL4 activating domain, GAL4 DNA-binding domain and *Gxs* (from Santa Cruz) (data not shown).

2.2. Two-hybrid assay

The yeast two-hybrid assay was performed using the Y190 yeast strain (from Clontech), which was transformed with the appropriate plasmids, using the lithium acetate procedure and grown on SD plates in the absence of Trp and Leu. Protein interaction analysis was

performed on SD plates without Leu, Trp and His (SD/Leu⁻,Trp⁻,His⁻). After 3 days at 30°C, individual colonies were streaked out and grown on SD/Leu⁻,Trp⁻ liquid medium and tested for β -galactosidase activity.

2.3. Quantitative β -galactosidase assay

Liquid culture assay for β -galactosidase was performed according to the instructions from the 'Luminescent β -gal Genetic Reporter System II' kit (from Clontech). Data for quantitative assays were corrected for yeast cell number and are the mean \pm S.E.M. of triplicate assays.

3. Results

In order to study the physical interaction between the AC cytosolic domains, we subcloned the full-length fragments that codify for C₁ and C₂ of xlAC9 and for C₂ of rAC6 into appropriate two-hybrid system vectors (Fig. 1). After transformation of the Y190 yeast cells with the corresponding recombinant plasmids, β -galactosidase activity was measured. As shown in Fig. 2, a very strong interaction between C₂ domains was observed, the highest occurring between homologous domains (rC₂-rC₂ and xlC₂-xlC₂). The C₁ domain, on the contrary, showed no β -galactosidase activity stimulation thus indicating no homodimerization between these cytosolic domains. As expected, heterodimerization between the C₁ and C₂ xlAC cytosolic domains was also detected.

After proving by Western analysis that the AC cytosolic domains were expressed (data not shown) and able to interact in our two-hybrid system, we continued to look at their interaction with *Gxs*. To perform this assay, we used the wild type and constitutively activated Q²¹²/L mutant of the short form of *hGxs* and xl*Gxs*. Interaction with the C₂ domain was observed, when the *hGxs* was tested, and this association was dependent on the activated state of the α subunit (Fig. 3). No interaction with C₁ was detected, confirming previous crystal-




Fig. 1. Schematic representation of the constructions used in the yeast two-hybrid system analysis. Letters above each diagram represent the restriction enzymes utilized to subclone the different PCR amplified cDNAs into pACT2 and pAS2-1 vectors. B = *BamHI*, Bg = *BglII*, E = *EcoRI*, N = *NcoI*, S = *SalI*, T = *Tth111I*. Letters and numbers below indicate the amino acid and its corresponding position in the cDNA, respectively. pAS1-ch1(Q/L) and pAS1-ch2(Q/L) correspond to pAS-ch1 and pAS-ch2 constructions with the Q²¹²/L mutation in the *Gxs* region. P53 and SV40Tag were used as a positive two-hybrid system control.




Fig. 2. Interaction of C₁ and C₂ domains of xl9AC and r6AC. Y190 were co-transformed with the indicated cDNA fragments subcloned in the two-hybrid vectors written on the left side of the figure. Transformants were grown in synthetic SD liquid medium without leucine and tryptophan at 30°C for three days and β-galactosidase activity was measured as described in Section 2.

lographic and biochemical studies performed with purified AC cytosolic fragments [19–23]. With the xlGαs, on the contrary, neither the wild type nor the activated mutant were able to interact with any of the cytosolic domains (data not shown). This result is in agreement with our previous findings which showed that the xlα subunit was not able to activate the S49 cyc⁻ AC in an ‘in vitro’ reconstituted system [30]. In that study we demonstrated, by the construction of chimeras between human and *Xenopus* Gαs, that a region within the N-terminal half, which constitutes the helical domain of the protein, was responsible for the lack of activation [30]. For this reason, we decided to test out the constitutively activated (Q/L) chimeric proteins for their physical interaction with the xlAC cytosolic domains. When coexpressed with the C₂ domain, ch2 (N-hGαs/C-xlGαs) but not ch1 (N-xlGαs/C-hGαs)




Fig. 3. Interaction of AC C₁ and C₂ domains with wild-type hGαs and mutant Gαs(Q/L). Experimental conditions are similar to those described in Fig. 2.




Fig. 4. Interaction of AC C₁ and C₂ domains of AC with Gαs chimeras ch1, ch1(Q/L), ch2 and ch2(Q/L). Experimental conditions are similar to those described in Fig. 2.

was able to stimulate the β-galactosidase reporter gene (Fig. 4), confirming the inability of ch1 to activate AC. In addition, since Gαi/Gαs chimeras were shown to activate AC to a higher extent than wild-type Gαs [31–34], we decided to also test them in the two-hybrid assay. As shown in Fig. 5, both Q/L mutated chimeras (ch9 and ch10) were not only able to interact with C₂, but also with a substantially higher affinity (compare Fig. 3 with Fig. 5), confirming the AC activation studies mentioned above. Surprisingly, ch9 (N-mGαi2/C-xlGαs) but not ch10 (N-mGαi2/C-hGαs) was able to interact very strongly with the C₁ AC cytosolic domain.

4. Discussion

We have expressed the full-length AC cytosolic domains C₁ and C₂ fused to the GAL4-DNA binding or activating domains and tested ‘in vivo’ for their capacity to interact. Protein-protein interaction was quantitated by measuring β-galactosidase activity with a highly sensitive chemiluminescent




Fig. 5. Interaction of AC C₁ and C₂ domains of AC Gαs with Gαi-Gαs chimeras. Chimera 9 and chimera 10 were constructed as indicated in Fig. 1 and co-transformed in Y190 with AC C₁ or C₂ domains as indicated in the bottom of the figure. Experimental conditions are similar to those described in Fig. 2.

assay. The two-hybrid system employed in this study has the advantage of allowing us to differentiate between homologous or heterologous interactions and also to estimate the relative interaction affinities that are proportional to the β -galactosidase activity.

Our results show that the full-length C_2 cytosolic domain of xlAC9 was able to homodimerize very strongly (similar to p53 with SV40TAg) and also to heterodimerize with a lower affinity to the C_1 domain of the same AC. This finding corroborates previous biochemical and crystallographic studies performed with fragments of C_1 and C_2 domains of heterologous AC [19–23]. Unfortunately, with the two-hybrid system used in this study, we were unable to look at the effect of Fk or G α s on C_1 – C_2 interaction that has been previously reported to substantially increase their affinity [26]. The xlAC9– C_1 domain, on the contrary, showed no capacity to homodimerize which contradicts the experiments reported by Sunahara et al. [26] performed with gel filtration, where it was shown that both cytosolic fragments were eluting as dimers. We believe that the reason for this discrepancy is the difference in size of the AC domains. In our study we used the complete C_1 cytosolic domains that is 486 aa long, whereas Sunahara et al. expressed only a fragment of it, that is half the size (227 aa) of the whole domain.

Using the same approach, we were also able to measure a weak interaction between the hG α s(Q/L) and the C_2 domain, but no interaction with C_1 . This finding is also in good agreement with crystallographic data, which showed that G α s was predominantly interacting with C_2 [27]. In addition, gel filtration and equilibrium sedimentation studies also corroborated the same results as well as the requirement of G α s to be in an active conformation in order to interact with C_2 . On the other hand, the lack of interaction observed with the xlG α s again corroborates and explains the inability of this α subunit to activate AC. We now believe, based on trypsin protection experiments (unpublished results), that the reason for this anomalous behavior is due to the incapacity of this protein to adopt the active conformation state necessary to interact with C_2 and to activate AC.

Interaction studies performed with G α i/G α s chimeras, that have previously shown to be better activators of AC than wild-type G α s, confirm these results. Since the hybrid chimeric proteins showed a considerably stronger interaction with C_2 than the normal G α s, this possibly indicates that these proteins tend to have a more permanent activated conformation.

Based on the pseudosymmetric structure adopted by the C_1 – C_2 heterodimer and to the simultaneous activating and inhibitory effect produced by G α s and G α i on AC, Tesmer et al. [27] have proposed a G α i interaction site in C_1 equivalent to the G α s binding site in C_2 . This hypothesis has now been confirmed by demonstrating the formation of a stable complex between GTP γ S–G α i and the C_1 (but not C_2) domain of type 5 AC [35]. Now that a C_1 –G α i interaction has been proven, we can better understand the behavior of ch9 which showed the capacity to interact with C_2 and C_1 . Since ch9 is a hybrid between G α i and G α s it is possible to speculate that the chimeric protein could adopt a conformation capable of binding to both domains. We do not know the reason why ch10 does not interact with C_1 , and further analyses are needed in order to understand these differences.

Acknowledgements: This study was supported by Grants No. 1971115 (J.O., M.V.H.) and No. 2980050 (M.T.) from FONDECYT and by Grant No. C95B01 (J.O., A.M.G.) from ECOS. We also would like to thank Lauren Jean Aguayo for critical reading of the manuscript.

References

- [1] Iyengar, R. (1993) FASEB J. 7, 768–775.
- [2] Taussig, R. and Gilman, A. (1995) J. Biol. Chem. 270, 1–4.
- [3] Sunahara, R.K., Dessauer, C.W. and Gilman, A. (1996) Annu. Rev. Pharmacol. Toxicol. 36, 461–480.
- [4] Seamon, K.B., Padgett, W. and Daly, J.W. (1981) Proc. Natl. Acad. Sci. USA 78, 3363–3367.
- [5] Olate, J., Mattera, R., Codina, J. and Birnbaumer, L. (1988) J. Biol. Chem. 263, 10394–10400.
- [6] Graziano, M.P., Freissmuth, M. and Gilman, A. (1989) J. Biol. Chem. 267, 409–418.
- [7] Harry, A., Chen, Y., Magnusson, R., Iyengar, R. and Weng, G. (1997) J. Biol. Chem. 272, 19017–19021.
- [8] Choi, E.J., Wong, S.T., Hinds, T.R. and Storm, D.R. (1992) J. Biol. Chem. 267, 12440–12442.
- [9] Dittman, A.H., Weber, J.P., Hinds, T.R., Choi, E.J. and Migeon, J.C. (1994) Biochemistry 33, 943–951.
- [10] Premont, R.T., Jacobowitz, O. and Iyengar, R. (1992) Endocrinology 131, 2774–2783.
- [11] Kawabe, J., Iwami, G., Ebina, T., Ohno, S. and Katada, T. (1994) J. Biol. Chem. 269, 16554–16558.
- [12] Wayman, G.A., Impey, S., Wu, Z.L., Kinds-Vogel, W., Prichard, L. and Strom, D.R. (1994) J. Biol. Chem. 269, 25400–25405.
- [13] Cooper, D.M., Mons, N. and Karpen, J.W. (1995) Nature 374, 421–424.
- [14] Iwami, G., Kawabe, J., Ebina, T., Cannon, P.J., Homcy, C.J. and Ishikawa, Y. (1995) J. Biol. Chem. 270, 12481–12484.
- [15] Tang, W.J., Lluhi-Iñiguez, J.A., Mumby, S. and Gilman, A. (1992) Cold Spring Harbor Symp. LVII, 135–144.
- [16] Clapham, D.E. and Neer, E.J. (1993) Nature 365, 403–406.
- [17] Taussig, R., Quarmby, L.M. and Gilman, A. (1993) J. Biol. Chem. 268, 9–12.
- [18] Tang, W.J. and Gilman, A. (1992) Cell 70, 869–872.
- [19] Tang, W.J. and Gilman, A. (1995) Science 268, 1769–1772.
- [20] Yan, S.Z., Hahn, D., Huang, Z.H. and Tang, W.J. (1996) J. Biol. Chem. 271, 10941–10945.
- [21] Whisnant, R.E., Gilman, A. and Dessauer, C.W. (1996) Proc. Natl. Acad. Sci. USA 93, 6621–6625.
- [22] Dessauer, C.W. and Gilman, A. (1996) J. Biol. Chem. 271, 16967–16974.
- [23] Scholich, K., Barbier, A.J., Mullenix, J.B. and Patel, T.B. (1997) Proc. Natl. Acad. Sci. USA 94, 2915–2920.
- [24] Zhang, G., Liu, Y., Ruoho, A.E. and Hurley, J.H. (1997) Nature 386, 247–253.
- [25] Yan, S.Z., Huang, Z.H., Rao, V.D., Hurley, J.H. and Tang, W.J. (1997) J. Biol. Chem. 272, 18849–18854.
- [26] Sunahara, R.K., Dessauer, C.W., Whisnant, R.E., Kleuss, C. and Gilman, A. (1997) J. Biol. Chem. 272, 22265–22271.
- [27] Tesmer, J.G., Sunahara, R.K., Gilman, A. and Sprang, S.R. (1997) Science 278, 1907–1916.
- [28] Scholich, K., Wittpoth, C., Barbier, A.J., Mullenix, J.B. and Patel, T.B. (1997) Proc. Natl. Acad. Sci. USA 94, 9602–9607.
- [29] Torrejón, M., Echeverría, V., Ratamales, G., Herrera, L., Hinrichs, M.V. and Olate, J. (1997) FEBS Lett. 404, 91–94.
- [30] Antonelli, M., Birnbaumer, L., Allende, J.E. and Olate, J. (1994) FEBS Lett. 340, 249–254.
- [31] Osawa, S., Dhanasekaran, N., Woon, C.W. and Johnson, G. (1990) Cell 63, 697–706.
- [32] Dhanasekaran, N., Osawa, S. and Johnson, G. (1991) J. Cell. Biochem. 47, 352–358.
- [33] Gupta, S.K., Dhanasekaran, N., Heasley, L.E. and Johnson, G. (1991) J. Cell. Biochem. 47, 359–368.
- [34] Berlot, C.H. and Bourne, H. (1992) Cell 68, 911–922.
- [35] Dessauer, C.W., Tesmer, J.J.G., Sprang, S.R. and Gilman, A. (1998) J. Biol. Chem. 273, 25831–25839.